Sygnature Discovery wins Medilink Outstanding Achievement Award

Sygnature Discovery emerged victorious at the Medilink UK Healthcare Virtual Business Awards 2020, securing the coveted Outstanding Achievement accolade that stands as a testament to the company’s remarkable progression and expansion across recent years.

The Medilink Business Awards are a prestigious platform aimed at showcasing excellence within the life sciences sector across five distinct categories: Start Up, Export Achievement, Collaboration with the NHS, Innovation, and the pinnacle, Outstanding Achievement. The dynamic virtual awards ceremony unfolded on the 8th of October 2020, and it was expertly hosted by the talented comedian and freestyle rapper, Chris Turner. The event served as an afternoon brimming with entertainment, jubilation, and invaluable networking opportunities alongside luminaries of the industry.

Having already secured victory in the regional East Midlands ceremony last year, Sygnature found itself in the national spotlight as a finalist for the esteemed Outstanding Achievement Award, generously sponsored by Mills & Reeve. Stepping onto the national stage, the award was gratefully accepted by a trio of Sygnature Discovery’s esteemed representatives: Dr. Paul Clewlow, Senior VP of Business Development; Dr. Paul Overton, Senior VP of Business Development; and Anders Lindstrom, Director of Marketing.

 

Paul Clewlow commented:

“What an honour to have won the national Outstanding Achievement Award. Our mission at Sygnature is to enable success for our customers and ultimately to help develop the treatments of the future that will improve the lives of patients across the globe. We have always believed in investing in the brightest and most committed scientists at Sygnature in order to accomplish that mission, and this award is a great recognition of the quality of our work and the determination of our team.”

Sygnature Discovery wins Medilink Outstanding Achievement Award

Latest News

View All

Sygnature Discovery goes for global industry recognition…

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…

Sygnature Discovery invests £3.75M in Compound Management…